1. Evaluation of basophil activation test in the management of immediate hypersensitivity reactions to gadolinium-based contrast agents: a five-year experience 
Camille Kolenda, Rolande Dubost, MD, Florence Hacard, MD, Christine Mullet, MD, Diane Le Quang, MD, Lorna Garnier, PharmD, Jacques Bienvenu, PharmD, PhD, Vincent Piriou, MD, PhD, Frédéric Bérard, MD, PhD, Françoise Bienvenu, PharmD, Sébastien Viel, PharmD, PhD 
The Journal of Allergy and Clinical Immunology: In Practice 
Volume 5, Issue 3, Pages (May 2017)
DOI: /j.jaip
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Figure 1
A, ROC curve for GD and GBCA-induced CD203c expression generated between GBCA− (n = 14) and GD+ (n = 11) or GBCA+ (n = 17) patients. B, Mean percentage of CD203c+ basophils tested with the culprit drug at the concentration of 1/10. ***P < .005. C, Outcomes of the 33 patients included in the study. BAT, Basophil activation test; G, gadobutrol; GA, gadoteric acid; GBCA, gadolinium-based contrast agent; GD, gadobenate dimeglumine; IHS, immediate hypersensitivity; ROC, receiver operating characteristic.
The Journal of Allergy and Clinical Immunology: In Practice 2017 5, DOI: ( /j.jaip )
Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions